Human Human vWF-A2 ELISA Kit

Cat No. ELI-M-020-96

Size: 96 tests

MOLEOULE-ON®

Components	Quantity		
Microwell Plate - antibody coated 96-well Microplate (8 wells ×12 strips)			
Standard - lyophilized, 3000 pg/ml upon reconstitution	2 Vials		
Concentrated Biotin-Conjugated antibody (100X) - 120 ul/vial	1 Vial		
Concentrated Streptavidin-HRP solution (40X) - 300 ul/vial	1 Vial		
Standard /sample Diluent - 16 ml/vial	1 Bottle		
Biotin-Conjugate antibody Diluent - 16 ml/vial	1 Bottle		
Streptavidin-HRP Diluent - 16 ml/vial	1 Bottle		
Wash Buffer Concentrate (20X) - 30 ml/vial	1 Bottle		
Substrate Solution - 12 ml/vial	1 Bottle		
Stop Solution - 12 ml/vial	1 Bottle		
Plate Cover Seals	2 pieces		

Reagent Preparations

Temperature returning - Bring all kit components and specimen to room temperature (20-25°C) before use.

Wash Buffer - Dilute 30mL of Wash Buffer Concentrate with 570mL of deionized or distilled water to prepare 600mL of Wash Buffer. If crystals have formed in the concentrate Wash Buffer, warm to room temperature and mix gently until the crystals have completely dissolved.


Standard\Specimen - Reconstitute the Standard with 0.5mL of Standard/Sample Diluent. This reconstitution produces a stock solution of 3000pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 250uL of Standard/Sample Diluent into 1500pg/ml tube and the remaining tubes. Use the stock solution of 3000pg/mL to produce a 2-fold dilution series (below). Mix each tube thoroughly and change pipette tips between each transfer. The 3000 pg/mL standard serves as the high standard. The Standard/Sample Diluent serves as the zero standard (0 pg/mL). *If you do not run out of re-melting standard, store it at -20°C. Diluted standard shall not be reused.

Working solution of Biotin-Conjugate anti-human vWF-A2 antibody: Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with the Biotin-Conjugate antibody Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.

Working solution of Streptavidin-HRP: Make a 1:40 dilution of the concentrated Streptavidin-HRP solution with the Streptavidin-HRP Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.



Storage

All components of Human vWF-A2 ELISA Kit should be store at 2-8°C except reconstituted standard that should be store at -20°C.

Description

Human vWF is a serum glycoprotein that mediates platelet adhesion to injured vascular endothelium. vWF function is regulated by ADAMTS13 mediated proteolysis within the A2 domain. Mutations of this protease cause thrombotic thrombocytopenic purpura.

Principle

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for vWF-A2 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any vWF-A2 present is captured by the coated antibody after incubation. Following extensive washing, a biotin-conjugate antibody specific for vWF-A2 is added to detect the captured vWF-A2 protein in sample. For signal development, horseradish peroxidase (HRP)-conjugated Streptavidin is added, followed by tetramethyl-benzidine (TMB) reagent. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.

Sample Collection And Storage

Cell Culture Supernates - Centrifuge cell culture media at 1000 Xg to remove debris. Assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 2 hours at room temperature or overnight at 2-8°C. Centrifuge at approximately for 15 minutes at $1000 \times g$. Assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at $1000 \times g$ within 30 minutes of collection. Assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.

Note: The normal human serum or plasma samples are suggested to make a 1:2 dilution.

Procedure

- 1. Prepare all reagents and working standards as directed in the previous sections.
- 2. Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2-8°C sealed tightly.
- 3. Add 100µl of standard or samples to each well and incubate for 90 minutes at 37°C.
- 4. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (350µl) using a multichannel pipette, manifold dispenser or auto-washer. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
- 5. Add 100µl working solution of Biotin-Conjugate anti-human vWF-A2 antibody to each well, incubate for 60 minutes at 37°C.
- 6. Repeat step 4.
- 7. Add 100µl working solution of Streptavidin-HRP to each well, incubate for 30 minutes at 37°C.
- 8. Repeat step 4 with an additional wash.
- 9. Add 100µl of Substrate Solution to each well. Incubate for 15 minutes at 37°C. Avoid placing the plate in direct light.
- 10. Add 50µl Stop solution to each well. Gently tap the plate to ensure thorough mixing.
- 11. Read at 450nm within 30 minutes.

Technical Note

- 1. When mixing or reconstituting protein solutions, always avoid foaming.
- 2. To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- 3. To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- 4. A standard curve should be generated for each set of samples assayed. According to the content of tested factors in the sample, appropriate diluted or concentrated samples, it is best to do pre-experiment.

Calculation of Results

- 1. The standard curve is used to determine the amount of specimens.
- 2. First, average the duplicate readings for each standard, control, and sample. All O.D. values are subtracted by the mean value of blank control before result interpretation.
- 3. Construct a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.
- 4. The data may be linearized by plotting the log of the vWF-A2 concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
- 5. This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

Standard (pg/ml)	OD.	OD.	Average	Corrected
0	0.048	0.040	0.044	-
46.88	0.180	0.169	0.174	0.130
93.8	0.262	0.245	0.253	0.209
188	0.389	0.365	0.377	0.333
375	0.618	0.579	0.599	0.555
750	1.004	0.941	0.972	0.928
1500	1.634	1.532	1.583	1.539
3000	2.663	2.496	2.580	2.536

Sensitivity, Specificity And Repeatability

SENSITIVITY: The minimum detectable dose was 23pg/mL.

SPECIFICITY: This assay recognizes both natural and recombinant human vWF-A2. The factors listed below were prepared at 100ng/ml in Standard /sample Diluent and assayed for cross-reactivity and no significant cross-reactivity or interference was observed.

REPEATABILITY: The coefficient of variation of both intra-assay and inter-assay were less than 10%.

RECOVERY: The recovery of vWF-A2 spiked to three different levels in four samples throughout the range of the assay in various matrices was evaluated.